The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sugaya, M.
Right arrow Articles by Hwang, S. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sugaya, M.
Right arrow Articles by Hwang, S. T.
The Journal of Immunology, 2006, 177: 7665-7672.
Copyright © 2006 by The American Association of Immunologists, Inc.

Oncostatin M Enhances CCL21 Expression by Microvascular Endothelial Cells and Increases the Efficiency of Dendritic Cell Trafficking to Lymph Nodes1

Makoto Sugaya2,3, Lei Fang3, Adela R. Cardones3, Takashi Kakinuma, Samer H. Jaber, Andrew Blauvelt4 and Sam T. Hwang5

Dermatology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892

CCL21, a lymphatic endothelial cell (LEC)-derived chemokine, and its receptor CCR7 regulate dendritic cell (DC) trafficking to lymph nodes (LN), but it is unclear how CCL21 expression is regulated. Oncostatin M (OSM) is an IL-6-like cytokine synthesized by activated DC and other leukocytes. In vitro, OSM (but not TNF-{alpha}) stimulated CCL21 mRNA and protein expression by human dermal microvascular EC (DMEC) in an ERK1/2-dependent fashion. Conditioned medium from OSM-treated DMEC stimulated CCL21-dependent chemotaxis of mouse bone marrow-derived DC (BMDC). Cultured BMDC expressed OSM, which was increased with the addition of LPS. Topical application of the contact-sensitizing hapten, trinitrochlorobenzene, resulted in enhanced OSM expression in the skin, whereas cutaneous injection of TNF-{alpha} did not. Injection of OSM into the footpad increased CCL21 mRNA expression in the draining LN by ~10-fold and in mouse skin by ~4-fold without increasing CCR7 mRNA. In vitro, OSM increased the permeability of DMEC and lung microvascular EC monolayers to FITC-dextran beads, and, in vivo, it enhanced accumulation of Evans blue dye in draining LN by ~3-fold (p = 0.0291). Of note, OSM increased trafficking of BMDC injected in footpads to draining LN by 2-fold (p = 0.016). In summary, OSM up-regulates CCL21 expression in skin and draining regional LN. We propose that OSM is a regulator of CCL21 expression and endothelial permeability in skin, contributing to efficient migration of DC to regional LN.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research. S.H.J. was supported by the National Institutes of Health Clinical Training Research Program.

2 Current address: Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo 113-8655, Japan.

3 M.S., L.F., and A.R.C. contributed equally to the execution of the study.

4 Current address: Departments of Dermatology and Molecular Microbiology and Immunology, Oregon Health & Science University and Dermatology Service, Veterans Affairs Medical Center, 3710 Southwest U.S. Veterans Hospital Road, R&D 55, Portland, OR 97239.

5 Address correspondence and reprint requests to Dr. Sam T. Hwang, Senior Investigator, 10 Center Drive, Room 12N258, Bethesda, MD, 20852. E-mail address: hwangs{at}mail.nih.gov

6 Abbreviations used in this paper: DC, dendritic cell; LN, lymph node; EC, endothelial cell; LEC, lymphatic EC; BVEC, blood vascular EC; DMEC, dermal microvascular EC; LYVE-1, lymphatic vascular EC-1; VEGF, vascular endothelial growth factor; OSM, oncostatin M; HDF, human dermal fibroblast; LMEC, lung microvascular EC; BMDC, bone marrow-derived DC; m, murine; for, forward; rev, reverse; RT, room temperature; rm, recombinant murine; rh, recombinant human; hOSM, human OSM; TNCB, trinitrochlorobenzene.




This article has been cited by other articles:


Home page
Cancer Res.Home page
A. Issa, T. X. Le, A. N. Shoushtari, J. D. Shields, and M. A. Swartz
Vascular Endothelial Growth Factor-C and C-C Chemokine Receptor 7 in Tumor Cell-Lymphatic Cross-talk Promote Invasive Phenotype
Cancer Res., January 1, 2009; 69(1): 349 - 357.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Hintzen, C. Haan, J. P. Tuckermann, P. C. Heinrich, and H. M. Hermanns
Oncostatin M-Induced and Constitutive Activation of the JAK2/STAT5/CIS Pathway Suppresses CCL1, but Not CCL7 and CCL8, Chemokine Expression
J. Immunol., November 15, 2008; 181(10): 7341 - 7349.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Pegu, S. Qin, B. A. Fallert Junecko, R. E. Nisato, M. S. Pepper, and T. A. Reinhart
Human Lymphatic Endothelial Cells Express Multiple Functional TLRs
J. Immunol., March 1, 2008; 180(5): 3399 - 3405.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.